Current status of dendritic cell-based tumor vaccination

Onkologie

Volumn 23, Issue 6, 2000, Pages 544-551

  Dannull, J ^a   Cerny, T ^a   Ackermann, D K ^a   Groettrup, M ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Dendritic cells; Immunotherapy; Tumor associated antigens; Vaccination

Indexed keywords

TUMOR ANTIGEN;

CANCER CELL; CANCER PATIENT; DENDRITIC CELL; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSTIMULATION; MONOCYTE; REVIEW; VACCINATION;

EID: 0034502615     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055004     Document Type: Review

References (28)

1. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation
2. The emerging role of CTLA-4 as an immune attenuator
3. Dendritic cells and the control of immunity
4. Proliferating dendritic cell progenitors in human blood
5. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha
6. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions
7. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
8. Serological analysis of human tumor antigens: Molecular definition and implications
9. The makings of a tumor rejection antigen
10. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy
11. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
12. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
13. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
14. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules
15. Fully mobilizing host defense: Building better vaccines
16. MHC class I- and class II-restricted processing and presentation of microencapsulated antigens
17. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells
18. Report from the International Union Against Cancer (UICC) Tumor Biology Committee: UICC workshop on the use of dendritic cells in cancer clinical trials
19. Follow-up evaluation of a phase II prostate cancer vaccine trial
20. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
21. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA
22. Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: Results of a phase I/II study
23. CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer
24. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells
25. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
26. Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue
27. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
28. Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets